Which is more appropriate for the evaluation of HCC, RECIST or mRECIST criteria?
We have read with great interest the recent article conducted by Dr Haghnejad and colleagues [1], published in Digestive and Liver Disease. This retrospective multicentre study enrolled all consecutive hepatocellular carcinoma (HCC) patients treated with atezolizumab plus bevacizumab after failing one or more multikinase inhibitors (MKIs) treatments (such as sorafenib). Finally, they included 50 patients in this analysis. With a median follow-up of 18.21 months, they found the objective response rate was 14 %, and the disease control rate was 56 %.
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Yong Xie, Tianshi Lyu, Jian Wang, Yinghua Zou Tags: Correspondence Source Type: research
More News: Avastin | Cancer & Oncology | Carcinoma | Gastroenterology | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Study | Urology & Nephrology